local_hospital

Belgyogyazati Klinika, Nephrologia-Hypertonia centrum, Dializis Központ

Address
Szökefalvi Nagy Bela Utca 4/b, 6720 Szeged, Hungary

Belgyogyazati Klinika, Nephrologia-Hypertonia centrum, Dializis Központ

This specialized nephrology and dialysis center focuses on comprehensive care for patients with chronic kidney disease and associated complications. The center combines expertise in internal medicine, nephrology, hypertension management, and dialysis services to provide integrated treatment for complex renal conditions.

  • Chronic kidney disease-associated pruritus (CKD-aP) management and treatment
  • Advanced dialysis services and renal replacement therapy
  • Hypertension management in chronic kidney disease patients

The center actively participates in clinical research investigating novel therapeutic approaches for chronic kidney disease-associated pruritus, a challenging and often debilitating symptom affecting dialysis patients. Through randomized controlled trials, the center evaluates innovative topical treatments aimed at improving quality of life for patients suffering from CKD-aP. This research focus demonstrates the center's commitment to addressing the full spectrum of complications related to chronic kidney disease beyond traditional renal function management.

Site Overview

assignment
2
connected trials
corporate_fare
1
sponsor
science
1
IMP

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
1
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 332 other sites in Hungary

description
Trial volume
2
Outperforms 37% of sites
public
Therapeutic diversity
1areas
Outperforms 2% of sites
groups
Sponsor diversity
1sponsors
Outperforms 2% of sites

Therapeutic Area Benchmark — Hungary

Select a therapeutic area to compare against other sites in Hungary.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Hungary

Market Share

Country: Hungary

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Belgyogyazati Klinika, Nephrologia-Hypertonia centrum, Dializis Központ

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to Evaluate the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in Subjects with Chronic Kidney Disease-associated Pruritus (CKD-aP)Mc2 Therapeutics LimitedPhase IINot RecruitingFeb 2023Feb 2024

IMP list

IMP Trials Status First start Last start
Alanyl Glutamine1Unknown2023-02-202023-02-20

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.